TG Therapeutics Inc
NASDAQ:TGTX 3:59:59 PM EDT
| Market Cap (Intraday) | 4.43B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $30.23 |
| 50-Day MA | $29.47 |
| 200-Day MA | $40.17 |
TG Therapeutics Inc Stock, NASDAQ:TGTX
2 Gansevoort Street, 9th floor, New York, New York 10014
United States of America
Phone: +1.212.554.4484
Number of Employees: 272
Description
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.